UroGen Pharma's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.51.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.08.
During the past 3 years, the average EBIT per Share Growth Rate was 26.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 14.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for UroGen Pharma's EBIT per Share or its related term are showing as below:
URGN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -67.8 Med: 5.5 Max: 26.9
Current: 26.9
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of UroGen Pharma was 26.90% per year. The lowest was -67.80% per year. And the median was 5.50% per year.
URGN's 3-Year EBIT Growth Rate is ranked better than 78.62% of 1305
companies
in the Biotechnology industry
Industry Median: 3.5
vs URGN: 26.90
UroGen Pharma's EBIT for the
three
months ended in Dec. 2023 was $-18.58 Mil.
UroGen Pharma EBIT per Share Historical Data
The historical data trend for UroGen Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (NAS:URGN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
UroGen Pharma EBIT per Share Related Terms
Thank you for viewing the detailed overview of UroGen Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
UroGen Pharma (UroGen Pharma) Business Description
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
URGN has been successfully added to your 